OBJECTIVES: Acute pulmonary hypertension following cardiac surgery can have a significant effect on postoperative morbidity and mortality. However, limited data are available on the efficacy and potency of clinically used systemic vasopressors on the pulmonary vasculature. The aim of this study was to use human pulmonary artery to characterize the pharmacological effects of clinically used vasopressors on the human pulmonary vasculature.
The differential effects of systemic vasoconstrictors on human pulmonary artery tension † 
INTRODUCTION
Pulmonary hypertension is defined as mean pulmonary artery (PA) pressure > _ 25 mmHg measured by right heart catheterization [1] . The most up-to-date classification of pulmonary hypertension, established at the World Health Organization pulmonary hypertension conference in Nice, France, in 2013, divided pulmonary hypertension into 5 subgroups on the basis of similar aetiology or characteristics [2] -group 1: PA hypertension; group 2: pulmonary hypertension due to left heart disease; group 3: pulmonary hypertension due to chronic lung disease or hypoxia; group 4: chronic thromboembolic pulmonary hypertension and group 5: pulmonary hypertension due to unclear multifactorial mechanisms. Pulmonary hypertension in cardiac surgery patients is more frequently classified as precapillary, capillary or post-capillary according to the anatomical location of the underlying mechanism [3] . Post-capillary pulmonary hypertension relates to clinical group 2, whereas precapillary pulmonary hypertension incorporates clinical groups 1, 3, 4 and 5. Pre-and post-capillary pulmonary hypertension can be distinguished on the basis of pulmonary wedge pressure, which is < _15 mmHg in precapillary pulmonary hypertension and >15 mmHg in post-capillary pulmonary hypertension [4] . Pulmonary hypertension in cardiac surgery patients is typically group 2 or post-capillary type because it is usually associated with left heart disease and the cause is localized in the post-pulmonary capillary bed [5] .
Pulmonary hypertension is an important prognostic factor in cardiac surgery and is associated with increased rates of morbidity and mortality. Patients are usually diagnosed with pulmonary hypertension prior to surgery but cardiac surgery itself can precipitate it. The mechanism of the underlying pathophysiology is complex, and pulmonary hypertension may exist prior to surgery or might develop during or after surgery [6] .
Vasopressor drugs are commonly used perioperatively and postoperatively to treat low systemic arterial blood pressure and maintain organ perfusion. The choice of vasopressor and inotropes in patients having cardiac surgery should take into account their effects on pulmonary vascular resistance because these drugs could trigger pulmonary vasoconstriction, which, if persistent, could progress to pulmonary hypertension [7] . Adrenaline (AD), noradrenaline (NA) and arginine vasopressin (AVP) are frequently used vasopressors in cardiac surgery patients. AD and NA are sympathomimetic catecholamines whose vasopressor effect is predominantly mediated by the activation of vascular smooth muscle a 1 -adrenoceptors, whereas vasoconstriction by AVP is mediated via activation of vascular smooth muscle V 1 receptors [8] .
Ideally, cardiac surgical patients need a vasopressor drug that can selectively cause systemic vasoconstriction without triggering pulmonary vasoconstriction. The effects of commonly used vasopressor agents on pulmonary vascular tone have been investigated extensively in animal models. However, limited data are available about the effects of vasopressors on human pulmonary vascular tone. In recent years, our group has used human PA rings to investigate the physiological and pharmacological effects on the human pulmonary vasculature of vasopressors. In this study, we used human PA rings to compare the efficacy and potency of clinically used vasopressors on human pulmonary vascular tone, which could lead to improved decision making in the perioperative and postoperative settings.
MATERIALS AND METHODS
Research ethics committee and local research and development department approval was obtained to use human tissue for this study. Patients gave written consent for the use of surplus tissue for research purposes. Patients under the age of 18 years and those who could not give informed consent were excluded from the study.
Isolation of pulmonary artery rings
Human pulmonary arteries were obtained from lungs or lobes of patients immediately following resection for cancer. Lengths of healthy vessel were exposed and resected by the operating surgeon, who took care to avoid the tumour margins, and placed in oxygenated (5% CO 2 : 21% O 2 ) Krebs-Henseleit solution (containing, in mM, NaCl 118, KCl 4.7, MgSO 4 1.2, NaHCO 3 25, KH 2 PO 4 1.2, CaCl 2 2.4 and glucose 11) before being transferred to the laboratory. After careful removal of adipose and connective tissue, the arteries were cut into 2-mm long rings with an internal diameter of 2-4 mm.
Mounting of pulmonary artery rings
A multiwire myograph system (DMT 620M) was used for mounting PA rings and measuring isometric tension. The multiwire myograph system consisted of 4 individual myograph units. Each unit was made of aluminium and had a centrally located 8-ml stainless steel chamber. The tissue-support pins were positioned in the chamber, with one side attached to a force transducer and the other side attached to a micrometre. PA rings were mounted between the pins. Each unit had individually controlled gas inflow and suction. Heating and connections for vacuum and gassing were in the myograph interface, permitting the preparations in all four chambers to be kept under physiological conditions (37 C and bubbled with 21% O 2 : 5% CO 2 ). The myograph system was connected to a PC via an amplifier (Power Lab 8/35, ADInstruments) for continuous measurement of isometric tension using data acquisition software (Lab Chart Pro Version 8., ADInstruments).
Effect of systemic vasopressors on pulmonary vascular tone
After mounting of the PA rings, a resting tension of 1.6 gram force (gf) was applied (optimum resting tension determined in preliminary experiments), and the vessels were left to equilibrate with 21% O 2 :5% CO 2 at 37 C for 60 min. When a stable resting tension was achieved, cumulative concentration response curves to the agonists [AD, NA, endothelin-1 (ET-1), prostaglandin F2a (PGF 2a ) , KCl and AVP] were constructed by stepwise increases in agonist concentration in the myograph chamber when a plateau response had been obtained to the preceding concentration. Active tension was calculated as maximum tension at plateau (gf) -resting tension (gf).
The maximum efficacy (E max ) for each agent was determined in gf and expressed as gf/mm internal diameter of each vessel (to take into account the variability in the diameter of the PA ring) or percentage of the control response curve E max KCl contraction. At the end of each experiment, the integrity of the endothelium was confirmed by the addition of 1 lM acetylcholine. KCl was used to check the contractility of PA rings; rings that did not contract in response to KCl were excluded from the study.
Agonist potency was compared by determining the agonist EC 50 concentration (the concentration required to elicit 50% of a maximum response), which was presented as pEC 50 (the negative logarithm of the molar EC 50 concentration).
Effect of arginine vasopressin on active tension in response to prostaglandin F2a
In another set of experiments, the potential vasodilator effect of AVP on pulmonary vascular tone was investigated. When a stable resting tension was achieved, vessels were preconstricted to 11.2 lM PGF 2a (EC 80 ). When a stable plateau contraction was achieved, the effect of AVP on active tension was determined by cumulative addition to the myograph chambers.
Chemicals and reagents
A 5% CO 2 /balance air was sourced from BOC Limited (Guilford, Surrey, UK). The agents used were (supplier in parentheses) AD (Martindale Pharmaceuticals, Buckinghamshire, UK), acetylcholine (Sigma-Aldrich, St. Louis, MO, USA), AVP (Mercury Pharmaceuticals, part of Concordia International, London, UK), ET-1 (American Peptide Company, part of Thermo Fisher Scientific, Waltham MA, USA), NA (Aguettant Pharmaceuticals, Bristol, UK) and PGF 2a (Tocris Bioscience, part of Bio-Techne, Abingdon, UK). Stock solutions of drugs were prepared using the solvents recommended by the suppliers, and control responses to solvents were obtained when necessary. Fresh serial dilutions were made, using the appropriate solvent, for each experiment. All other reagents were obtained from Thermo Fisher Scientific unless otherwise stated.
Statistical analysis
Data are presented as mean ± standard deviation (SD), and n represents the number of individual PA rings used in an experiment. Agonist EC 50 concentrations (the concentration required to elicit 50% of maximum response) were determined using nonlinear regressions to fit a standard slope model using the statistical analysis functions of GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla, CA, USA. More details can be found at http://www.graphpad.com/guides/prism/6/curve-fitting/index. htm). Agonist potency is presented as pEC 50 (the negative logarithm of the molar EC 50 concentration). Significance was taken as P < 0.05.
RESULTS
A total of 57 human PA rings (mean internal diameter 2.8 ± 0.4 mm) were obtained from 19 patients.
Concentration-dependent effects of vasopressors on human pulmonary arteries
AD, NA, ET-1, PGF 2a and KCl caused the concentrationdependent vasoconstriction of human pulmonary arteries, whereas AVP had no significant effect (Figs 1-6 ). The order of efficacy (expressed as gf, gf/mm internal diameter or percentage of KCl E max ) was KCl = PGF 2a > A = NA > ET-1 and the order of potency was ET-1 > A = NA > PGF 2a > KCl. The effects of vasopressor agents on PA tone are summarized in Table 1 and Fig. 7 .
E max (gf) for AD, NA, ET-1, PGF2a, KCl and vasopressin was 0.84 gf, 0.66 gf, 0.34 gf, 1.11 gf, 1.08 gf and 0.004 gf, respectively. Another useful indicator of the variation in the internal diameter of the PA rings is a comparison of the total active force of a 2-mm-long artery segment normalized for internal diameter. Using this index, the values (E max [gf/mm]) for AD, NA, ET-1, PGF2a, KCl and vasopressin were 0.08 gf/mm, 0.077 gf/mm, 0.035 gf/mm, 0.141 gf/mm, 0.121 gf/mm and 0.0004 gf/mm, respectively.
By taking the maximum response to KCl as 100%, the value of E max (% KCl) to AD, NA, ET-1 and PGF2a ranges was 78%, 61%, 31% and 102%, respectively.
Effect of arginine vasopressin on active tension in response to prostaglandin F 2a AVP (0.01-3 mM) had no effect on active tension to PGF 2a (n = 4 from 2 patients).
Concentration response curve of NA-induced pulmonary vasoconstriction
All vessels constricted in response to NA. Increasing concentrations of NA from 3 nM to 30 mM were used on 12 PA rings. Maximal contraction was seen at 3 mM (log -5.5M); after that, the response of vessels to NA tailed off. The EC20, EC50 and EC80 were 40.09 nM, 150 nM and 563.55 nM, respectively. The hill slope was 1.049 ± 0.595.
Concentration response curve of ET-1-induced pulmonary vasoconstriction
To evaluate the effect of ET-1 on pulmonary vessels, 8 PA rings and concentrations of ET-1 from 100 pM-30 nM were used. As the concentration rose above 1 nM, vessels started constricting and the maximum contractile response was seen at 10 nM (log -8 M). The EC20, EC50 and EC80 were 0.95 nM, 1.46 nM and 2.26 nM, respectively. The hill slope was 3.199 ± 2.154.
Concentration response curve of PGF 2a -induced pulmonary vasoconstriction
PGF2a at a concentration of 100 nM-300 mM was used on 8 PA rings to demonstrate its vasoconstriction effect. The EC20, EC50 and EC80 were 3.6 mM, 6.35 mM and 11.21 mM, respectively. The hill slope was 2.441 ± 1.239.
Concentration response curve of KCl-induced pulmonary vasoconstriction
A total of 13 PA rings were studied in this series. Increasing concentrations of KCl from 300 mM to 300 mM were used. Vessels Figure 1 : Concentration response curve to AD. A total of 8 pulmonary artery rings from 4 patients were used to determine the effect of AD on the pulmonary artery. Concentrations from 3 nM to 30 mM (1E-8.5 M-1E-4.5 M) were used for these experiments. All vessels constricted in response to AD; the maximal response was at 3 mM (log -5.5 M). The EC20, EC50 and EC80 were 97.6 nM, 246 nM and 622 nM, respectively. Concentration response curve to noradrenaline (NA). All vessels constricted in response to NA. Increasing concentrations of NA from 3 nM to 30 mM were used on 12 pulmonary artery rings from 4 different patients. Maximal contraction was seen at 3 mM (log -5.5M); after that, the response of the vessels to NA tailed off. The EC20, EC50 and EC80 were 40.09 nM, 150 nM and 563.55 nM, respectively. The hill slope was 1.049. Concentrations from 100 pM to 30 nM (1E-10 M-1E-7.5 M) were used. As the concentration increased above 1 nM, the vessels started constricting; the maximum contractile response was seen at 10 nM (log -8 M). The EC20, EC50 and EC80 were 0.95 nM, 1.46 nM and 2.26 nM, respectively. The hill slope was 3.199. Figure 4 : Concentration response curve to prostaglandin F2a (PGF2a). Concentrations of PGF2a from 100 nM to 300 mM (1E-7 M-1E-3.5 M) were used on 8 pulmonary artery rings from 3 different patients to demonstrate its vasoconstriction effects. The EC20, EC50 and EC80 were 3.6 mM, 6.35 mM and 11.21 mM, respectively. The hill slope was 2.441. Figure 5 : Concentration response curve to KCl. A total of 13 pulmonary artery rings from 4 different patients were studied in this series. Increasing concentrations of KCl from 300 mM to 300 mM (1E-3.5 M-1E-0.5 M) were used. Vessels started contracting when the concentration was above 1 mM (log -3M); maximal contraction was seen at 100 mM; after that, the response to KCl diminished. The EC20, EC50 and EC80 were 7.98 mM, 17.29 mM and 37.46 mM, respectively. The hill slope was 1.794. Concentrations from 10 pM to 3 mM (1E-11 M-1E-5.5 M) were used to generate a concentration response curve, but no significant effect was seen. Diameter: internal diameter of pulmonary artery rings; E max (gf): maximum contractile response measured in gf; E max (g/mm): maximum average response to the vasopressor agent as g force normalized per mm of averaged internal circumference; gf: gram force; pEC50: the negative logarithm of the molar concentration required to elicit 50% maximum response; EC50: molar concentration of the drug that gives half the maximal response.
started contracting as the concentration increased above 1 mM (log -3M); the maximal contraction was seen at 100 mM; after that, the response to KCl diminished. The EC20, EC50 and EC80 were 7.98 mM, 17.29 mM and 37.46 mM, respectively. The hill slope was 1.794.
Concentration response curve of arginine vasopressin-induced pulmonary vasoreactivity
To demonstrate the effect of AVP on PA rings, a concentration of AVP of 10 pM-3 mM was used with no effect.
DISCUSSION
This study is the first to demonstrate the differential in vitro effects of clinically used vasopressors and endogenous vasopressors on small human pulmonary vessels. AD, NA and ACP are frequently used as systemic vasopressors in patients having cardiac surgery. ET-1 and PGF 2a are endogenous vasoconstrictors that are thought to play an important role in maintaining and regulating endogenous vascular tone.
AD and NA are catecholamine sympathomimetic agents that act as agonists of the sympathetic nervous system via adrenoceptors. Adrenoceptors are 7 trans-membrane spanning, G-protein-coupled cell membrane receptors that are divided into 2 main groups, a and b, that are further subdivided into a 1 , a 2 , b 1 b 2 and b 3 [9] . NA acts predominantly on vascular smooth muscle a 1 adrenoceptors, whereas AD acts on both a and b adrenergic receptors. Vascular smooth muscle has 2 types of alpha-adrenoceptors: alpha 1 (a 1 ) and alpha 2 (a 2 ), and both adrenoceptors mediate vasoconstriction and maintain basal vascular tone [10] . The a 1 adrenoceptors are located predominantly on vascular smooth muscle and cause vasoconstriction via the Gq-inositol triphosphate signal transduction pathway by increasing intracellular calcium, whereas a 2 -adrenoceptors are found on the smooth muscle cells and are linked to Gi or Go proteins, which on activation increase the Ca 2+ through voltage gated Ca 2+ channels [11] . This study illustrates that the constrictor potency of AD (pEC 50 6.6) is comparable to that of NA (pEC 50 6.8) and is likely due to their similar affinities for a 1 and a 2 adrenoceptors, as demonstrated by van Brummelen et al. [12] . The distribution of human a 1 adrenergic receptors varies with the vascular bed, and the PA a 1 adrenoceptor density is reported to be 24 ± 5.2 fmol/mg total protein [13] . Our study demonstrates that the pEC 50 of NA was 6.82, and the reported pEC 50 values in human coronary, internal mammary, inferior epigastric and gastroepiploic arteries ranged from 5.9 to 6.6 [14] .
ET-1 is a 21-amino acid peptide, mainly secreted by vascular endothelial cells, lung fibroblasts and PA smooth muscle cells, that causes vascular smooth muscle contraction via stimulation of its receptors [15] . ET-1 acts through ET A receptors found in smooth muscle cells and cardiac myocytes and ET B receptors found in smooth muscle and endothelial cells [16] . Activation of smooth muscle cell endothelin receptors triggers phospholipase C, which causes vasoconstriction by increasing the levels of inositol triphosphate, diacylglycerol and intracellular calcium. Activation of endothelial ET B receptors results in the release of nitric oxide (NO) and prostacyclin and mediates endothelial dependent vasodilation [17] . In human lungs, ET A receptors are present predominantly in the large pulmonary arteries, whereas ET B receptors are present in airway smooth muscles, capillaries and the alveolar wall. The intravenous administration of ET-1 results in a biphasic response in humans with initial vasodilation followed by sustained vasoconstriction [18] . The initial vasodilator response is due to NO release and potassium channel activation [18] . Pulmonary vasoconstriction results from the activation of both ET A and ET B receptors, because blockade of both receptors is necessary to accomplish the maximum inhibition of ET-1-induced vasoconstriction [19] . An ET-1 receptor antagonist, e.g. Bosentan (dual ET A and ET B receptor antagonist) proved to be an effective treatment in pulmonary hypertension [20] . Our study shows that ET-1 is more potent than other vasoconstrictors (the pEC 50 for ET-1, NA, AD, PGF 2a and KCl was 8.83, 6.82, 6.6, 5.19 and 1.76, respectively), and our calculated pEC 50 of ET-1 (8.83) for human PA is comparable to that reported for human coronary (8.21) and mammary arteries (8.55) [21] .
AVP is a neurohypophysial hormone that acts both as a vasopressor and antidiuretic hormone. It is released in response to decreased arterial pressure and increased plasma osmolality and mediates vasoconstriction, reabsorption of water and central nervous system effects through its V 1 , V 2 and V 3 receptors [8] . The Figure 7 : Cumulative concentration response curve to adrenaline (AD) (᭜, n = 8), noradrenaline (NA) (᭡, n = 12), endothelin 1 (ET-1) (*, n = 8), prostaglandin F2a (PGF2a) (x, n = 8), KCl (, n = 13) and vasopressin (•, n = 8). The findings show that PGF2a and KCl equally caused maximal constriction, whereas ET-1 had less effect and vasopressin had no effect. The order of efficacy was KCl = PGF2a > AD > NA > ET-1, and the order of potency was ET-1 > AD = NA > PGF2a > KCl. The EC50 for AD, NA, ET-1, PGF2a and KCl was 246 nM, 150 nM, 1.46 nM, 6.35 mM and 17.24 mM, respectively. activation of vasopressin V 1 receptors on vascular smooth muscles results in vasoconstriction via the activation of the Gq protein of phospholipase C and in an increase in intracellular Ca 2+ [22] . V 2 receptors are found on renal distal tubules and collecting duct, and their stimulation results in reduced diuresis via activation of adenylate cyclase and an increase in cAMP [23] . V 3 receptors are located in the pituitary gland and are involved in the release of adrenocorticotropic hormone via phospholipase C. Both in vivo and in vitro studies on animals show that vasopressin causes PA vasodilation [24] . The authors also conclude that vasopressin mediates vasodilation through the release of NO because the vasodilatory response of vasopressin was diminished when the NO synthesis inhibitor L-NNA was inserted [24, 25] . The intravenous administration of vasopressin in normotensive and hypertensive patients causes no effect on PA pressure, as showed by Nelson et al. [26] . On the other hand, an increase in PA pressure was found when intravenous vasopressin was given to patients with advanced tuberculosis and liver cirrhosis [27, 28] . Our study found that vasopressin had no vasodilatory or vasoconstrictor effect on the PA. This result might be due to lack of V 1 receptors in the human PA or a lack of peptides involved in NOvasopressin vasodilation. Therefore, AV may be safe to use for systemic vasoconstriction in patients with pulmonary hypertension [29] .
PGF 2a is an endogenous vasoconstrictor that causes vasoconstriction via activation of the prostaglandin F receptor, which is a G-protein-coupled receptor located on the pulmonary vascular smooth muscle. KCl grounds the depolarization of smooth muscles that leads to vasoconstriction via calcium entry through voltage gated calcium channels [30] . This study shows that PGF 2a (E max 1.1 gf) and KCl (E max 1.08 gf) cause maximal constriction equally.
Other commonly used perioperative vasoconstrictors, e.g. phenylephrine and metaraminol, were not investigated. These agents are predominantly a 1 -adrenoceptor agonists; it is generally agreed that their use as a systemic vasopressor is contraindicated in patients with pulmonary hypertension.
CONCLUSION
This study demonstrated the differential effect of commonly used agonists on pulmonary vascular reactivity, with PGF2a and KCl causing equal amounts of maximal constriction. In contrast, ET-1 had less effect and vasopressin had no effect. One may need to consider these effects in the clinical setting because they might result in the development of pulmonary hypertension. Vasopressin may be safe to use for systemic vasoconstriction in patients with pulmonary hypertension. Surgical patients need an ideal vasopressor drug that can selectively cause systemic vasoconstriction without triggering pulmonary vasoconstriction. Further studies need to be performed to validate the data.
